|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trails-Other |
The Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77005
2 Address correspondence and reprint requests to Frederick F. Lang, Department of Neurosurgery, Box 442, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030-4009.
Abstract
Although no optimal treatment is currently available for malignant brain tumors, as the molecular mechanisms underlying brain tumor development have been delineated, new chemotherapeutic agents that act directly on specific molecular targets have become available. Defining a specific molecular target raises the possibility that the molecular effects of a given agent can be analyzed in patients in a clinical trial. Specifically, whereas standard phase I and II clinical trials classically determine the safety and efficacy of agents by using indirect global end points, these new biological agents afford the opportunity to incorporate molecular end points into phase I and II clinical trials to determine whether the agent under investigation is actually doing what it was intended to do. This work presents avenues for improving current brain tumor clinical trial designs based on the molecular specificity of new agents and the unique features of brain tumors. Specifically, the authors recommend brain-applicable phase I and II clinical trial strategies that take advantage of the targeted nature of new agents to maximize information about their efficacy, toxicity, and molecular effects.
References
Begemann, M., Fuller, G.N., and Holland, E.C. (2002) Genetic modeling of glioma formation in mice. Brain Pathol. 12,117 -132.[ISI][Medline]
Bigner, S.H., Humphrey, P.A., Wong, A.J., Vogelstein,B., Mark, J.,
Freidman,H.S., Bigner, D.D. (1990) Characterization of the
epidermal growth factor receptor in human glioma cell lines and xenografts.
Cancer Res. 50,8017
-8022.
Bogler, O., Nagane, M., Gillis, J., Huang, H.J., and Cavenee, W.K.
(1999) Malignant transformation of p53–deficient astrocytes
is modulated by environmental cues in vitro. Cell Growth
Differ. 10,73
-86.
Davies, M.A., Lu, Y., Sano, T., Fang, X., Tang, P., LaPushin, R.,
Koul, D., Bookstein, R., Stokoe, D., Yung, W.K., Mills, G.B., and Steck, P.A.
(1998) Adenoviral transgene expression of MMAC/PTEN in human
glioma cells inhibits Akt activation and induces anoikis. Cancer
Res. 58,5285
-5290.
Ding, H., Roncari, L., Shannon, P., Wu, X., Lau, N., Karaskova, J.,
Gutmann, D.H., Squire, J.A., Nagy, A., and Guha, A. (2001)
Astrocyte-specificexpression of activated p21–ras results in malignant
astrocytoma formation in a transgenic mouse model of human gliomas.
Cancer Res. 61,3826
-3836.
Dowlati, A., Haaga, J., Remick, S.C., Spiro, T.P., Gerson, S.L.,
Liu, L., Berger, S.J., Berger, N.A., and Willson, J.K. (2001)
Sequential tumor biopsies in early PHASE clinical trials of anticancer agents
for pharmacodynamic evaluation. Clin. Cancer Res.
7,2971
-2976.
Eisenhauer, E.A. (1998) Phase I and II trials of novel
anti-cancer agents: Endpoints, efficacy and existentialism. The Michel Clavel
Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy,
Amsterdam, 16–19 June 1998. Ann. Oncol.
9,1047
-1052.
Feldkamp, M.M., Lala, P., Lau, N., Roncari, L., and Guha, A. (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45,1442 -1453.[CrossRef][ISI][Medline]
Feldkamp, M.M., Lau, N., Roncari, L., and Guha, A.
(2001) Isotype-specific Ras.GTP-levels predict the efficacy of
farnesyl transferase inhibitors against human astrocytomas regardless of Ras
mutational status. Cancer Res.
61,4425
-4431.
Frankel, R.H., Bayona, W., Koslow, M., and Newcomb, E.W.
(1992) p53 mutations in human malignant gliomas: Comparison of
loss of heterozygosity with mutation frequency. Cancer
Res. 52,1427
-1433.
Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor, I., Haglund, M.M., Ashley, D.M., Rich, J., Dolan, M.E., Pegg, A.E., Moschel, R.C., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., and Schold, S.C., Jr. (1998) Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16,3570 -3575.[Abstract]
Gelmon, K.A., Eisenhauer, E.A., Harris, A.L., Ratain, M.J., and
Workman, P. (1999) Anticancer agents targeting
signalingmoleculesand cancer cell environment: Challenges for drug
development? J. Natl. Cancer Inst.
91,1281
-1287.
Gilbert, M.R. (2000) Brain tumor clinical trials: Pitfalls and promise for the future. Curr. Oncol. Rep. 2, 473-475.[Medline]
Guha, A., Dashner, K., Black, P.M., Wagner, J.A., and Stiles, C.D. (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60,168 -173.[ISI][Medline]
Guha, A., Feldkamp, M.M., Lau, N., Boss, G., and Pawson, A. (1997) Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15,2755 -2765.[CrossRef][ISI][Medline]
Hanahan,D., and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100,57 -70.[CrossRef][ISI][Medline]
Henson, J.W., Schnitker, B.L., Correa, K.M., von Deimling, A., Fassbender, F., Xu, H.J., Benedict, W.F., Yandell, D.W., and Louis, D.N. (1994) The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol. 36,714 -721.[CrossRef][ISI][Medline]
Hess, K.R., Wong, E.T., Jaekle, K.A., Kyritsis, A.P., Levin, V.A., Prados, M.D., and Yung, W.K. (1999) Response and progression in recurrent malignant glioma. Neuro-Oncol. 1, 282-288.[Abstract]
Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller, G.N. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25,55 -57.[CrossRef][ISI][Medline]
Houghton, P.J., Stewart, C.F., Thompson, J., Santana, V.M., Furman, W.L., and Friedman, H.S. (1998) Extending principles learned in model systems to clinical trials design. Oncology (Huntingt.) 12 (Suppl. 6),84 -93.
Ichimura, K., Schmidt, E.E., Goike, H.M., and Collins, V.P. (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13,1065 -1072.[ISI][Medline]
James, C.D., Carlbom, E., Dumanski, J.P., Hansen, M., Nordenskjold,
M., Collins, V.P., and Cavenee, W.K. (1988) Clonal genomic
alterations in glioma malignancy stages. Cancer Res.
48,5546
-5551.
Ke, L.D., Shi, Y.X., Im, S.A., Chen, X., and Yung, W.K.
(2000) The relevance of cell proliferation, vascular endothelial
growth factor, and basic fibroblast growth factor production to angiogenesis
and tumorigenicity in human glioma cell lines. Clin. Cancer
Res. 6,2562
-2572.
Kilic, T., Alberta, J.A., Zdunek, P.R., Acar, M., Iannarelli, P.,
O'Reilly, T., Buchdunger, E., Black, P.M., and Stiles, C.D.
(2000) Intracranial inhibition of platelet-derived growth
factor-mediated glioblastoma cell growth by an orally active kinase inhibitor
of the 2–phenylaminopyrimidine class. Cancer
Res. 60,5143
-5150.
Kleihues, P., and Cavenee, W.K. (2000) Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press.
Lang, F.F., Miller, D.C., Pisharody, S., Koslow, M., and Newcomb, E.W. (1994) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9, 949-954.[ISI][Medline]
Lang, F.F., Jr., Fuller, G.N., Prados, M., and Yung, W.A. (2000) Preliminary results of a phase I clinicaltrial of adenovirus-mediatedp53 gene therapy for recurrent gliomas: Biological studies. Proc. Am. Soc. Clin. Oncol. 19, 455a.
Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A., and Schlessinger, J. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313,144 -147.[CrossRef][Medline]
Louis, D.N., Holland, E.C., and Cairncross, J.G.
(2001) Glioma classification: A molecular reappraisal.
Am. J. Pathol. 159,779
-786.
Mauro, M.J., O'Dwyer, M., Heinrich, M.C., and Druker, B.J.
(2002) STI571: A paradigm of new agents for cancer
therapeutics.J. Clin. Oncol.
20,325
-334.
Mendel, D.B., Laird, A.D., Smolich, B.D., Blake, R.A., Liang, C., Hannah, A.L., Shaheen, R.M., Ellis, L.M., Weitman, S., Shawver, L.K., and Cherrington, J.M. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15, 29-41.[Medline]
Merritt, J.A., Roth, J.A., and Logothetis, C.J. (2001) Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies. Semin. Oncol. 28 (Suppl. 16),105 -114.[CrossRef][ISI][Medline]
Mishima, K., Johns, T.G., Luwor, R.B., Scott, A.M., Stockert, E.,
Jungbluth, A.A., Ji, X.D., Suvarna, P., Voland, J.R., Old, L.J., Huang, H.J.,
and Cavenee, W.K. (2001) Growth suppression of intracranial
xenografted glioblastomas overexpressing mutant epidermal growth factor
receptors by systemic administration of monoclonal antibody (mAb) 806, a novel
monoclonal antibody directed to the receptor. Cancer
Res. 61,5349
-5354.
Nagane, M., Coufal, F., Lin, H., Bogler, O., Cavenee, W.K., and
Huang, H.J. (1996) A common mutant epidermal growth factor
receptor confers enhanced tumorigenicity on human glioblastoma cells by
increasing proliferation and reducing apoptosis. Cancer
Res. 56,5079
-5086.
Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C., and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342,705 -708.[CrossRef][Medline]
Plecha, D.M., Goodwin, D.W., Rowland, D.Y., Varnes, M.E., and
Haaga, J.R. (1997) Liver biopsy: Effects of biopsy needle caliber
on bleeding and tissue recovery. Radiology
204,101
-104.
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E.E., and
Collins, V.P. (1993) Amplification and overexpression of the MDM2
gene in a subset of human malignant gliomas without p53 mutations.
Cancer Res. 53,2736
-2739.
Sabiers, J.H., Berger, N.A., Berger, S.J., Haaga, J.R., Hoppel, C.L., and Willson, J.K.V. (1993) Phase I trial of topotecan administered as a 72 hour infusion. Proc. Am. Assoc. Cancer Res. 34,426 .
Sano, T., Lin, H., Chen, X., Langford, L.A., Koul, D., Bondy, M.L.,
Hess, K.R., Myers, J.N., Hong, Y.K., Yung, W.K., and Steck, P.A.
(1999) Differential expression of MMAC/PTEN in glioblastoma
multiforme: Relationship to localization and prognosis. Cancer
Res. 59,1820
-1824.
Smith, J.S., Tachibana, I., Passe, S.M., Huntley, B.K., Borell,
T.J., Iturria, N., O'Fallon, J.R., Schaefer, P.L., Scheithauer, B.W., James,
C.D., Buckner, J.C., and Jenkins, R.B. (2001) PTEN mutation, EGFR
amplification, and outcome in patients with anaplastic astrocytoma and
glioblastoma multiforme. J. Natl. Cancer Inst.
93,1246
-1256.
Sonoda, Y., Ozawa, T., Hirose, Y., Aldape, K.D., McMahon, M.,
Berger, M.S., and Pieper, R.O. (2001a) Formation of intracranial
tumors by genetically modified human astrocytes defines four pathways critical
in the development of human anaplastic astrocytoma. Cancer
Res. 61,4956
-4960.
Sonoda, Y., Ozawa, T., Aldape, K.D., Deen, D.F., Berger, M.S., and
Pieper, R.O. (2001b) Akt pathway activation converts anaplastic
astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.
Cancer Res. 61,6674
-6678.
Spiro, T.P., Gerson, S.L., Liu, L., Majka, S., Haaga, J., Hoppel,
C.L., Ingalls, S.T., Pluda, J.M., and Willson, J.K. (1999)
O6–benzylguanine: A clinical trial establishing the biochemical
modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Cancer Res. 59,2402
-2410.
Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H., and Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15,356 -362.[CrossRef][ISI][Medline]
Szende, B., Romics, I., Minik, K., Szabo, J., Torda, I., Lovasz, S., Szomor, L., Toth, L., Bely, M., Kerenyi, T., Bartok, K., and Vegh, A. (2001) Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma. Prostate 49, 93-100.[CrossRef][ISI][Medline]
Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A., and
Louis, D.N. (1996) CDKN2/p16 or RB alterations occur in the
majority of glioblastomas and are inversely correlated. Cancer
Res. 56,150
-153.
Van Dyke, T., and Jacks, T. (2002) Cancer modeling in the modern era: Progress and challenges. Cell 108,135 -144.[CrossRef][ISI][Medline]
Walker, A.E., Robins, M., and Weinfeld, F.D. (1985)
Epidemiology of brain tumors: The national survey of intracranial neoplasms.
Neurology 35,219
-226.
This article has been cited by other articles:
|
|
 |
|
  S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium Neuro-oncol, August 1, 2008; 10(4): 631 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Ballman, J. C. Buckner, P. D. Brown, C. Giannini, P. J. Flynn, B. R. LaPlant, and K. A. Jaeckle The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro-oncol, January 1, 2007; 9(1): 29 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Heimberger, E. Wang, E. C. McGary, K. R. Hess, V. K. Henry, T. Shono, Z. Cohen, J. Gumin, R. Sawaya, C. A. Conrad, et al. Mechanisms of action of rapamycin in gliomas Neuro-oncol, January 1, 2005; 7(1): 1 - 11. [Abstract] [PDF]
|
|
|
|
 |
|
 V. K. Puduvalli, W.K. A. Yung, K. R. Hess, J. G. Kuhn, M. D. Groves, V. A. Levin, J. Zwiebel, S. M. Chang, T. F. Cloughesy, L. Junck, et al. Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study J. Clin. Oncol., November 1, 2004; 22(21): 4282 - 4289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Perry and J. G. Cairncross Glioma Therapies: How to Tell Which Work? J. Clin. Oncol., October 1, 2003; 21(19): 3547 - 3549. [Full Text] [PDF]
|
|
|
|
|
|
F. F. Lang, J. M. Bruner, G. N. Fuller, K. Aldape, M. D. Prados, S. Chang, M. S. Berger, M. W. McDermott, S. M. Kunwar, L. R. Junck, et al. Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results J. Clin. Oncol., July 1, 2003; 21(13): 2508 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fueyo, R. Alemany, C. Gomez-Manzano, G. N. Fuller, A. Khan, C. A. Conrad, T.-J. Liu, H. Jiang, M. G. Lemoine, K. Suzuki, et al. Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway J Natl Cancer Inst, May 7, 2003; 95(9): 652 - 660. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
